Both in Biotechnology
Denali Therapeutics vs Tarsus Pharmaceuticals
Over the past year DNLI returned +43.3% and TARS returned +32.0%; their daily moves had a correlation of 0.32.
DNLI +43.3% TARS +32.0%Growth of $1, one year, split-adjusted
| Metric | DNLI | TARS |
|---|---|---|
| Price | $20.81 | $76.69 |
| Market cap | $3.33B | $3.59B |
| Today | −0.81% | −0.16% |
| 1 month | −13.3% | +6.9% |
| 6 months | +15.1% | +14.6% |
| Year to date | +26.0% | −6.3% |
| 1 year | +49.2% | +36.2% |
| Revenue growth (YoY) | — | +69.4% |
| Gross margin | 97.4% | 93.0% |
| Net margin | −3539.2% | −10.7% |
| P/E (TTM) | — | — |
| Price / sales | 923.0× | 5.9× |
| Net cash | $705.0M | $376.9M |
| Dividend yield | — | — |
| Volatility (60d) | 50.0% | 54.0% |
| Short % of float | 12.9% | 16.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).